Search Results

You are looking at 1 - 10 of 35 items for :

  • "bisphosphonate" x
Clear All

A simple ion chromatographic (IC) method was developed and validated for simultaneous or individual determination of zoledronic, alendronic, pamidronic acids and their related substances in pharmaceutical formulation. The analytes were separated on Waters IC-Pak Anion HR analytical column with a nitric acid (3 mM) without any other additives, as mobile phase at a flow rate of 1.0 mL min−1. Inverse UV detection was used at 240 nm. Important chromatographic factors that influence the chromatography responses were screened by 11/12 Pluckett–Burman design and their interaction were assayed by 23 full factorial design. The RP-HPLC method was optimized with the aid of LC-Simulator® (ACD Labs, Toronto, Ontario, Canada) software. Validated method was successfully used for quantitative analysis of PAMIFOS®, concentrate for infusion (Habitfarm AD, Ivanjica, Serbia), ZOMETA®, powder for infusion (Novartis Pharma, Stein AG, Switzerland) and BONAP® tablets (Hemofarm, Vrsac, Serbia). Total chromatographic analysis time per sample was approximately 6 min, which represents significant improvement over existing methods. Validation studies revealed that the method is specific, rapid, reliable, and reproducible. Calibration plots were linear over the concentration ranges 20–120 μg mL−1 and 0.1–2 μg mL−1 for bisphosponates and their related substances, respectively. The LODs were 8.7, 4.7, 2.5, 0.026 and 0.011 μg mL−1 for alendronate, pamidronate, zoledronate, phosphoric acid and phosphorous acid, respectively.

Restricted access
Authors: Zsolt Horváth, Péter Farkas, Erna Ganofszky, Erika Hitre, Éva Juhos, Tünde Nagy, Gábor Rubovszky, Eszter Szabó and István Láng

Irodalom 1. S Adami N Zamberlan 1996 Adverse effects of bisphosphonates: a

Restricted access
Authors: Ferenc Koppány, Árpád Joób-Fancsaly, Zsolt Németh, Andrea Alexandra Belik, Mihály Vaszilkó, Edvárd Márton Varmuzsa and Krisztián Benedek Csomó

-Khashan HI, Mishriky AM, et al. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011; 32: 830–835. 6 Kaposvári I

Open access

References 1 Christodoulou, C., Pervena, A., Klouvas, G., et al.: Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the

Restricted access
Authors: Szófia Szentpéteri, László Restár, Zsolt Németh and Mihály Vaszilkó

Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63

Open access

–2768. Brozoski, M. A., Traina, A. A., Deboni, M. C., et al.: Bisphosphonate-related osteonecrosis of the jaw. Rev. Bras. Reumatol., 2012, 52 (2), 265–270. Ruggiero, S. L., Dodson, T. B., Fantasia, J., et al.: American

Restricted access

the jaw – 2014 update. J Oral Maxillofac Surg. 2014; 72; 1938–1956. 2 Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and

Open access

Biszfoszfonát-kezelés során fellépő állcsontnecrosis

Gyakorlati útmutató a biszfoszfonáttal kezelt betegeknél fellépő osteonecrosis megelőzéséhez és kezeléséhez

Authors: Enikő Udvardy, Pál Redl and Ildikó Márton

. 3. B Mehrotra S Ruggiero 2006 Bisphosphonate complications including osteonecrosis of the jaw

Restricted access

2008 Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 420 432

Restricted access

YC Shen 2009 Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells Cancer Lett

Restricted access